27 11, 2023

Amphastar Pharmaceuticals, Inc. Powers Higher Towards Its August 9 All-Time High: Jump in Right Now?

By |2023-11-27T17:19:35+00:00November 27th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , , |

By Leslie N. Masonson, MBA Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH), is a bio-pharmaceutical firm, that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products to its customers  in the United States, China, and France.  The company was incorporated in 1996 in Rancho Cucamonga, California where it is currently headquartered. It has [...]

Read More
23 10, 2023

Walgreens is Up 3% On Excitement Over New CEO & Bullish Outlook – VectorVest Still Says Sell

By |2023-11-08T15:39:41+00:00October 23rd, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , , , |

Shares of Walgreens Boots Alliance (WBA) started Monday morning trading strong with a 3% gain thus far. The stock has been battered in both the short and long term, but there is hope that new CEO Tim Wentworth will turn things around for the company. According to Lisa Gill, analyst at J.P. Morgan, today [...]

Read More
17 10, 2023

Johnson & Johnson Beats Earnings & Raises Forecast – So Why is the Stock Falling?

By |2023-11-08T15:41:38+00:00October 17th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Yesterday, we highlighted Pfizer’s challenges in pivoting as a post-pandemic company. Today, its competitor Johnson & Johnson (JNJ) reported earnings itself.  But, Johnson & Johnson painted an entirely different picture - beating out the earnings estimate on the top and bottom line while raising the forecast for the remainder of the year. The company [...]

Read More
16 10, 2023

Why is Pfizer Up 5% After Cutting Sales Outlook? 3 Things Investors Need to See

By |2023-11-08T15:41:50+00:00October 16th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Pfizer (PFE) ended last week on a sour note, announcing after the market closed on Friday that it will cut $9 billion from its sales outlook. And yet, the stock is up more than 5% so far in Monday morning’s trading session. The full-year EPS has been adjusted to $1.45 to $1.65 on revenue [...]

Read More
13 09, 2023

Is Rocket Pharmaceuticals a Buy as the Stock Soars on FDA Trial Update? 3 Things to Consider

By |2023-09-13T17:57:29+00:00September 13th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Gene therapy developer Rocket Pharmaceuticals (RCKT) investors woke up in delight as shares skyrocketed in Wednesday morning’s pre-market trading session. When the bell sounded, the stock continued its trajectory and it currently sits 38% higher than it last closed at. This comes after the company announced that it has aligned with the Food and [...]

Read More
20 07, 2023

Johnson & Johnson Jumps 6% on Earnings Beat and Revised Guidance: Does it Deserve a Buy?

By |2023-07-20T17:24:46+00:00July 20th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

Johnson & Johnson (JNJ) has had its ups and downs over the past few months, but it appears as if steady growth is ahead. The company has boosted its previous guidance for the year after Thursday’s earnings report came in well above analyst expectations. Johnson & Johnson saw sales growth of 6.3% for the [...]

Read More
18 07, 2023

AudioCodes is Down 55% This Year, and it May Get Worse: Time to Sell?

By |2023-07-19T16:45:56+00:00July 18th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Recursion Pharmaceuticals (RXRX) just got an endorsement from one of Wall Street’s hottest stocks at the moment, and as such, has earned the attention of analysts, retail investors, and professionals alike. After securing a $50 million investment from Nvidia (NVDA), the RXRX shot up more than 76%. The two companies are more alike than [...]

Read More
30 06, 2023

Is it Time to Sell Walgreens Stock Amidst Dwindling Consumer Spending & COVID-Vax Demand?

By |2023-06-30T18:10:48+00:00June 30th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

Earlier this week, Walgreens (WBA) warned investors that profits would take a dive from previous estimates as a result of weakened consumer spending and dwindling demand for COVID-19 vaccinations. As a result, shares dropped more than 9% this week - now reaching their lowest levels in over a decade. CEO Rosalind Brewer noted that [...]

Read More
27 06, 2023

One Analyst Predicts Canopy Growth is Headed to Zero, Should You Cut Losses and Move On?

By |2023-06-27T15:48:26+00:00June 27th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

At one point, Canopy Growth (CGC) was valued at $19 billion. The stock traded at over $50/share at its peak. But today? It sits at a mere $0.49/share. And as dramatic a fall from grace as this story already is, one analyst expects the true end is near. Benchmark analyst Mike Hickey believes Canopy [...]

Read More
26 06, 2023

Eli Lilly is Up 38% in the Past 3 Months: What Keeps Pushing the Stock Higher, and Will it Continue?

By |2023-06-26T18:30:02+00:00June 26th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

While much of the recent focus within the stock market has been placed on the AI trend, one stock in the pharmaceutical industry has been on a surge so far this year: Eli Lilly (LLY). The stock sat at just $311/share at the start of March. And today, the stock sits at $452/share. But, [...]

Read More
99¢ Trial Offer: Cyber Week Sale!
Got it!
X
Go to Top